Review
doi: 10.1016/j.jacc.2016.03.519.
Epub 2016 Apr 1.
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents
- PMID: 27046161
- DOI: 10.1016/j.jacc.2016.03.519
Item in Clipboard
Review
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents
J Am Coll Cardiol.
.
Free article
No abstract available
Keywords: ACC Expert Consensus Decision Pathway; ASCVD; LDL-C; PCSK9 inhibitors; bile acid sequestrants; cholesterol; dyslipidemia; ezetimibe; lipids; statins.
Similar articles
-
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.J Am Coll Cardiol. 2017 Oct 3;70(14):1785-1822. doi: 10.1016/j.jacc.2017.07.745. Epub 2017 Sep 5. J Am Coll Cardiol. 2017. PMID: 28886926
-
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee.J Am Coll Cardiol. 2022 Oct 4;80(14):1366-1418. doi: 10.1016/j.jacc.2022.07.006. Epub 2022 Aug 25. J Am Coll Cardiol. 2022. PMID: 36031461 No abstract available.
-
Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.Curr Atheroscler Rep. 2017 Jun;19(6):29. doi: 10.1007/s11883-017-0666-x. Curr Atheroscler Rep. 2017. PMID: 28500517 Review.
-
Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events.Curr Cardiol Rep. 2018 May 25;20(7):55. doi: 10.1007/s11886-018-0997-4. Curr Cardiol Rep. 2018. PMID: 29802475 Review.
-
Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.Ann Pharmacother. 2017 Oct;51(10):914-920. doi: 10.1177/1060028017714003. Epub 2017 Jun 19. Ann Pharmacother. 2017. PMID: 28627235
Cited by
-
Lipid-Lowering Medications for Managing Dyslipidemia: A Narrative Review.Cureus. 2024 Jul 23;16(7):e65202. doi: 10.7759/cureus.65202. eCollection 2024 Jul. Cureus. 2024. PMID: 39176329 Free PMC article. Review.
-
The Effectiveness and Safety of Intensive Lipid-Lowering with Different Rosuvastatin-Based Regimens in Patients at High Cardiovascular Disease Risk: A Nonblind, Randomized, Controlled Trial.Rev Cardiovasc Med. 2023 Aug 1;24(8):222. doi: 10.31083/j.rcm2408222. eCollection 2023 Aug. Rev Cardiovasc Med. 2023. PMID: 39076713 Free PMC article.
-
NHHR: An Important Independent Risk Factor for Patients with STEMI.Rev Cardiovasc Med. 2022 Dec 9;23(12):398. doi: 10.31083/j.rcm2312398. eCollection 2022 Dec. Rev Cardiovasc Med. 2022. PMID: 39076652 Free PMC article.
-
New Insights Into the Treatment of Hyperlipidemia: Pharmacological Updates and Emerging Treatments.Cureus. 2024 Jun 24;16(6):e63078. doi: 10.7759/cureus.63078. eCollection 2024 Jun. Cureus. 2024. PMID: 38919858 Free PMC article. Review.
-
The effect of lipid-lowering therapy on lipid-related residual risk factors: a prospective study.Lipids Health Dis. 2024 May 7;23(1):134. doi: 10.1186/s12944-024-02078-0. Lipids Health Dis. 2024. PMID: 38715079 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
